INmune Bio
INMB
33 hedge funds and large institutions have $18.2M invested in INmune Bio in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 3 closing their positions.
56% more capital invested
Capital invested by funds: $11.7M → $18.2M (+$6.55M)
38% more call options, than puts
Call options by funds: $590K | Put options by funds: $426K
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
1.11% more ownership
Funds ownership: 10.07% → 11.18% (+1.1%)
6% less funds holding
Funds holding: 35 → 33 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$1.43M |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$318K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$109K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$88.5K |
| 5 |
Millennium Management
New York
|
+$84.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$238K |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$121K |
| 3 |
Renaissance Technologies
New York
|
-$119K |
| 4 |
FAIM
Financial Advocates Investment Management
Olympia,
Washington
|
-$92.4K |
| 5 |
Squarepoint
New York
|
-$84.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $14.3K | -$3.75K | -467 | -23% |
|
|
VNA
27
Valley National Advisers
Bethlehem,
Pennsylvania
| $10K | – | – | – |
|
|
ADL
28
Asset Dedication LLC
San Francisco,
California
| $7K | – | – | – |
|
|
CA
29
Clearstead Advisors
Cleveland,
Ohio
| $3.81K | – | – | – |
|
|
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $3.63K | – | – | – |
|
|
IA
31
IFP Advisors
Tampa,
Florida
| $1.67K | – | – | – |
|
32
Fidelity Investments
Boston,
Massachusetts
| $772 | -$56 | -7 | -8% |
|
|
33
Squarepoint
New York
| – | -$84.3K | -13,045 | Closed |
|
|
FAIM
34
Financial Advocates Investment Management
Olympia,
Washington
| – | -$92.4K | -11,500 | Closed |
|
|
ASN
35
Advisory Services Network
Atlanta,
Georgia
| – | -$581 | -90 | Closed |
|
INMB Hedge Fund Activity: Q2 2023 in Review
33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2023, worth a combined $18.2M — up 56% from $11.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of INMB and 1 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was Rhenman & Partners Asset Management, opening a new position worth an estimated $1.43M. The largest seller was Susquehanna International Group, cutting an estimated $238K.
- 33 institutional investors held INmune Bio (INMB) as of Q2 2023, down from 35 in Q1 2023.
- Funds reported $18.2M of INmune Bio stock for Q2 2023, up 56% quarter-over-quarter.
- 1 fund opened new INmune Bio positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest INmune Bio buyer in Q2 2023 was Rhenman & Partners Asset Management, an estimated $1.43M added.
- The largest INmune Bio seller in Q2 2023 was Susquehanna International Group, an estimated $238K sold.
Based on aggregated 13F filings for Q2 2023.